Kidney Drug Plan Divides Transplant And Dialysis Supporters

The New York Times: “A Congressional proposal to help pay for drugs needed by transplant recipients to prevent rejection of donated kidneys has run into opposition from dialysis providers, drug companies and the National Kidney Foundation.” The groups support extending Medicare drug coverage but say the measure would cut funding for dialysis. “The proposal has created a rift between those in the business of providing dialysis and those in the business of performing transplants. The discord is being felt on Capitol Hill, and supporters of the measure fear it may make it easy for Congress to kill the provision altogether in the late stages of negotiation.” Meanwhile, the House health overhaul bill “includes a provision that would provide Medicare coverage for immunosuppressant drugs for all beneficiaries for life, starting in 2012.” But the issue is currently not addressed in the Senate health bill, though “the second-ranking Democrat in the Senate, Richard J. Durbin of Illinois, last week submitted an amendment that replicates the House language, giving the provision a badly needed lift” (Sack, 12/14).

This information was reprinted from kaiserhealthnews.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Health Policy Report, search the archives and sign up for email delivery at kaiserhealthnews.org.

© Henry J. Kaiser Family Foundation. All rights reserved.

source : www.medicalnewstoday.com

Related News:

• NEI/FDA To Hold One-Day Glaucoma Endpoints Meeting
• Higher-Strength Donepezil Pill Wins FDA Nod
• FDA Okays New Hypertension Polypill
• Oakland City Council approves industrial marijuana facilities
• European Medicines Agency Confirms Positive Benefit-Risk Balance Of Topical Formulations Of Ketoprofen
• 90 percent of scientists backing Avandia diabetes drug had financial ties to drug companies
• Epizyme Scientists Detail Epigenetic Approaches To Cancer Therapy In Drug Discovery Today
• AACE, American Diabetes Association And The Endocrine Society Joint Statement On Potential Cardiovascular Risks Associated With Rosiglitazone
• Scientific Leaders Urge Type 2 Diabetes Patients To Remain On Their Prescribed Medications Unless Instructed Otherwise By Their Health Care Provider
• FDA Adds Liver Failure Warning to RA Drug

Details :
Submited at Wednesday, December 16th, 2009 at 1:00 pm on Urology by chuck
Comment RSS 2.0 - leave a comment - trackback